Studies focusing on their target genes are required not only for the development of VEGF-based revascularization strategies for cardiovascular diseases but also for anti-VEGF therapies suitable for the treatment of cancer-related angiogenesis (Koch et al., 2011; Tugues et al., 2011; Ylä-Herttuala et al., 2017). The gene discussed is VEGFA; the disease is cancer.